DaVita Clinical Research Expands Capabilities With Investments in Central Laboratory

Published on: 

Company News Release

DaVita Clinical Research

announced the company’s recent investment in its Central Laboratory, servicing pharmaceutical, biotechnology, and medical device industries.
The investment was applied to analytical methodology, information technology (IT), and instrumentation in support of DCR’s continued drive to serve its clients. Over the past three years, DCR has had a strategic focus on Central Laboratory services, investing in state-of-the-art capital equipment, infrastructure and laboratory expansion/remodeling. The investment was placed in DCR’s Central Laboratory to ensure continuous delivery of customized care and satisfaction to its patients.
The Central Laboratory uses the latest in laboratory instrumentation. Some examples of the lab’s instrumentation and test menu include:

  • 7 Olympus 5400

  • 17 Siemens Centaur

  • 9 Tosoh G-8

  • 2 Liaison Diasorin

  • 8 Perkin-Elmer ICP-MS

  • 2 Nova

  • 2 Dianex

  • 23 Siemens Advia 2120

  • 2 TOPS Coagulation

  • 19 BACTEC 9240

  • 14 Lonza BioTek

  • 4 Vitek-2

DCR’s Central Laboratory also has invested in such technology as centrifuges, auto samplers, slide strainers, incubators, biosafety cabinets and decappers. DCR’s investment assisted in expanding and remodeling the laboratory, adding space to help facilitate future service expansion. In addition, extensive investment in its Falcon LabTM software application has resulted in the latest release, which includes an industry-leading report package.
At DCR’s Central Laboratory, individual trial samples are tracked using

LabScope Online

®, which ensures most specimen turnaround time of 24 hours or less.

The DCR Central Laboratory team is led by medical technologists, medical technicians and clinical pathologists, and receives formal guidance from nephrologists in the industry.